HTTIF (HighTide Therapeutics) Cash per Share: $0.14 (As of Dec. 2025)


HTTIF HighTide Therapeutics Inc HTTIF
14 GF Score
Price $0.39
! 3 Warning Signs
View Full Analysis

What is HighTide Therapeutics Cash per Share?

HighTide Therapeutics HTTIF 14 Cash per Share is $0.14 as of Dec. 2025. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). HighTide Therapeutics's Cash per Share for the quarter that ended in Dec. 2025 was $0.14.

HighTide Therapeutics  (OTCPK:HTTIF) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

HighTide Therapeutics Cash per Share Related Terms

HighTide Therapeutics Cash per Share Historical Data

* Premium members only.

The historical data trend for HighTide Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HighTide Therapeutics Cash per Share Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
0.23 0.47 0.20 0.13 0.14

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash per Share Get a 7-Day Free Trial Premium Member Only 0.20 0.15 0.13 0.13 0.14
HTTIF
14GF Score
HighTide Therapeutics Inc HTTIF
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HighTide Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

HighTide Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=71.377/508.72
=0.14

HighTide Therapeutics's Cash per Share for the quarter that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=71.377/508.72
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $0.14 mean?
HighTide Therapeutics (HTTIF) has a Cash per Share of $0.14 as of Dec. 2025. Cash per share is the per-share value of a company's available cash. View historical data for HighTide Therapeutics and its competitors.
Is HighTide Therapeutics' Cash per Share too high?
HighTide Therapeutics' current Cash per Share is $0.14. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' Cash per Share compare to VRTX and REGN?
HighTide Therapeutics' Cash per Share of $0.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for HighTide Therapeutics and its competitors. HighTide Therapeutics's current Cash per Share is $0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current Cash per Share of $0.14. The current Cash per Share is $0.14. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current Cash per Share is $0.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HighTide Therapeutics Business Description

Other Exchanges 02511:Hong Kong
Address Fubao Street, 9th to 10th Floor, Building D, Shenfang Park, Futian District, Shenzhen-Hong Kong Science and, Technology Innovation Cooperation Zone, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score

Get the complete analysis for HTTIF

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price